Jushi Holdings Inc.
JUSHFOTCHealthcare · Medicinal Chemicals & Botanical Products · A1 · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $262.9M | $257.5M | $269.4M | $284.3M | $209.3M | $80.8M |
| Operating income | $4.9M | $10.9M | −$2.8M | −$220.3M | −$35.8M | −$16.6M |
| Net income | −$68.6M | −$48.8M | −$65.1M | −$202.3M | $20.3M | −$210.6M |
| Total assets | $422.3M | $440.3M | $463.4M | $529.3M | $652.0M | — |
| Total liabilities | $537.7M | $490.6M | $471.0M | $483.4M | $471.1M | — |
| Equity | −$115.3M | −$50.2M | −$6.2M | $47.3M | $182.4M | $2.4M |
| EPS (diluted) | $-0.35 | $-0.25 | $-0.33 | $-1.44 | $-0.42 | $-1.94 |
| Shares out. | 196.7M | 196.6M | 196.6M | 204.2M | 201.6M | 108.5M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- 1.8%
- Net margin
- −26.1%
- Return on equity
- 59.5%
- Return on assets
- −16.2%
- Return on capital (ROCE)
- 1.4%
- Liabilities / assets
- 127.3%
- Debt / equity
- —
- Book value / share
- $-0.59
- Revenue growth (YoY)
- 2.1%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -4.96distress
- Accruals / assets
- −20.4%clean
- Beneish M-Score
- -2.64normal
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 severe● 2 warning● 5 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Operating margin is positive
- Strong return on equity (>15%)
- Revenue is growing year-over-year
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Mar 15, 2024
- NT 10-Kmissed a reporting deadline ↗Mar 31, 2023
- NT 10-Qmissed a reporting deadline ↗Nov 15, 2022
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Healthcare Of Ontario Pension Plan Trust FundPassive (13G)Feb 13, 2026
- Cacioppo JamesActivist (13D)Dec 15, 2025
- Marex Securities Products Inc.Passive (13G)Nov 26, 2025
- Nomura Holdings IncPassive (13G)May 15, 2025
- Arsenault Denis J.Passive (13G)Feb 14, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Cacioppo JamesOfficer — Chief Executive Officer | Dec 11, 2025 | Grant | 3.0M | $0.50 |
| Mosier Michelle OOfficer — Chief Financial Officer | Nov 13, 2024 | Buy | 3,666 | $0.35 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 112,504 | 1.0 | -76.9% |
| Apr 30, 2026 | 486,997 | 1.0 | +65.5% |
| Apr 15, 2026 | 294,270 | 1.9 | -45.8% |
| Mar 31, 2026 | 542,933 | 1.5 | +299.7% |
| Mar 13, 2026 | 135,833 | 1.0 | +423.0% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 12, 2026
- Other material eventApr 24, 2026
- Results of operationsMar 31, 2026
- Director / officer changeJan 6, 2026
- Director / officer changeDec 16, 2025
- Results of operationsNov 4, 2025
- Entered a material agreement · New financial obligation · Regulation FD disclosureSep 22, 2025
- Results of operationsAug 5, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 10-QMay 12, 2026
- 8-KFORM 8-KMay 12, 2026
- ARSMay 11, 2026
- DEFA14AMay 11, 2026
- DEF 14AMay 11, 2026
- PRE 14AApr 24, 2026
- 8-KFORM 8-KApr 24, 2026
- DEFA14AFORM DEFA14AApr 24, 2026
- 10-K/AApr 14, 2026
- 10-KMar 31, 2026
- 8-KFORM 8-KMar 31, 2026
- SCHEDULE 13G/AFeb 13, 2026
- 8-KJan 6, 2026
- 8-KDec 16, 2025
- 4FORM 4Dec 15, 2025
Event-driven situations (3)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.